Articles

This approval marks the fifth indication for Keytruda-based regimens in non-small cell lung cancer and the 34th indication in the United States.

FDA Approves Keytruda for Lung Cancer After Surgery 

AstraZeneca is developing a next-generation long-acting antibody for pre-exposure prophylaxis of COVID-19, which it plans to make available in the second half of 2023.



FDA Removes Evusheld’s EUA for COVID-19

Evio is launching a new pharmacy solution that leverages Flipt’s proprietary, cloud-based benefit administration and patient engagement platforms.

Flipt, Evio Partner on Pharmacy Benefit Solution for Employers

The Peripheral and Central Nervous System Drugs Advisory Committee meeting is scheduled for March 22, 2023, to review Biogen’s tofersen.

FDA to Hold Advisory Committee Meeting for ALS Drug

Once-daily, oral SGLT2 inhibitor Brenzavvy has been shown to reduce blood sugar and improve glycemic control.

FDA Approves New Drug for Type 2 Diabetes

A phase 3 trial showed that Jardiance reduced the risk of kidney disease progression or cardiovascular death in adults with chronic kidney disease by 28% compared with placebo. An FDA decision is expected in the second half of 2023.

FDA Accepts Jardiance sNDA for CKD Indication

Moderna plans to submit to the FDA its investigational mRNA vaccine, RNA-1345, for respiratory syncytial virus (RSV) in the first half of 2023.



Moderna Banks on COVID-19, RSV Vaccines

Lilly expects topline results from the confirmatory phase 3 trial in the second quarter of 2023 and plans to submit for full approval.

 FDA Issues Complete Response for Lilly Alzheimer’s Drug

This is the fourth indication for the Bruton’s tyrosine kinase inhibitor.

FDA Approves Brukinsa for Chronic Lymphocytic Leukemia

Tukysa with trastuzumab is indicated for second-line treatment of HER2-positive metastatic colorectal cancer, the first such therapy for this cancer.

All News